following a full submission assessed under the orphan equivalent medicine process
spesolimab (Spevigo®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
In a double-blind, phase II study, spesolimab, compared with placebo, significantly increased the proportion of adults with a moderate-to-severe flare of GPP who achieved pustular clearance.
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- spesolimab (Spevigo)
- SMC ID:
- SMC2729
- Indication:
For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 March 2025